Drug
Clazosentan clinical trials
Also written ACT-108475.
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses clazosentan is read from its arms, and is right about nine times in ten.
Testing it · 7
- Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the BrainCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03585270Written as Clazosentan
- Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical ClippingCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT00558311Written as Clazosentan
- A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart FunctionCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03657446Written as Clazosentan
- A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of ClazosentanCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03596294Written as Clazosentan
- Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid HemorrhageCompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT02560532Written as Clazosentan
- Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)CompletedPhase 2Idorsia Pharmaceuticals Ltd.NCT00111085Written as Clazosentan 1 mg/h
- Clazosentan in Aneurysmal Subarachnoid HemorrhageTerminatedPhase 3Idorsia Pharmaceuticals Ltd.NCT00940095Written as Clazosentan 5 m/h
Codes
What other systems call clazosentan · ClinicalTrials.gg INT004037
- MeSH (NLM) C109641clazosentanOne source NLM
- UNII (FDA) 3DRR0X4728CLAZOSENTANConfirmed FDA, NLM, Wikidata
- Wikidata Q1099339clazosentanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79486ClazosentanOne source FDA
- DrugBank DB06677One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C109641 | clazosentan | One source NLM |
| UNII (FDA) | 3DRR0X4728 | CLAZOSENTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q1099339 | clazosentan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79486 | Clazosentan | One source FDA |
| DrugBank | DB06677 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.